Carregant...
Novel agents in multiple myeloma
The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of Imids and proteasome inhibitors. However, majority of MM patients relapse and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including...
Guardat en:
| Publicat a: | Cancer J |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6589825/ https://ncbi.nlm.nih.gov/pubmed/30694859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000355 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|